Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Lennar Corporation (LEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Lennar Corporation — how do they compare? Definium Therapeutics Inc. Common Shares trades at $35.95 (market cap $4.71B), while Lennar Corporation trades at $78 (market cap $18.10B). The key difference: Lennar Corporation is far larger — about 3.8× Definium Therapeutics Inc. Common Shares's market cap, and Lennar Corporation pays a 2.63% dividend while Definium Therapeutics Inc. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Lennar Corporation for 67 Days on average.
| DFTX | LEN | |
|---|---|---|
Market Cap | $4.71B | $18.10B |
Volume | 1,966,636 | 5,229,157 |
Sector | Health | Consumer Cyclical |
52-Week High | $48.45 | $133.13 |
52-Week Low | $10.68 | $74.44 |
Typical Hold Time | 0 Days | 67 Days |
Enterprise Value | $3.67B | $22.52B |
Dividend Yield | — | 2.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Lennar (LEN) trades at $76.13, down 1.65% on the day, with technical indicators showing bearish momentum. The stock trades below book value (P/B 0.84) and at a discount to peers (P/E 14.42), but faces headwinds from declining revenue and net income margins. Recent news highlights Berkshire Hathaway's growing stake (now 11.2% as of Sept 30, 2026) while Morgan Stanley issued a sell rating, reflecting divergent views on the housing recovery timeline.
The outlook remains challenged by high mortgage rates and weak builder sentiment, though Berkshire's accumulation suggests long-term value. Key risks include the Hunterbrook short report alleging questionable transactions and ongoing margin pressure. With earnings missing estimates for three consecutive quarters and Q3 guidance cut, near-term catalysts appear limited despite attractive valuation metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →
